Ex vivo tumor derived organoid pharmacotyping identifies personalized therapeutic options for biliary tract cancer patients
{{output}}
Biliary tract cancers (BTCs) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient derived tumor organoid (PDTO) based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 t... ...
